Join today and have your say! It’s FREE!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}

Join today with :

or

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Sign in with existing account
Please Try Again
{{ error }}

Sign In With :

or

Password Hint : {{passwordHint}}
Forgot Password?
Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Shareholder Alert: Robbins Arroyo LLP Reminds Investors Inogen, Inc. (INGN) Sued for Misleading Shareholders

INGN

SAN DIEGO & GOLETA, Calif.

Shareholder rights law firm Robbins Arroyo LLP reminds investors that shareholders of Inogen (NASDAQ: INGN) filed a class action complaint against the company for alleged violations of the Securities Exchange Act of 1934 between November 8, 2017 and February 26, 2019. Inogen is a medical technology company that primarily develops, manufactures, and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients.

If you suffered a loss as a result of Inogen's misconduct, click here.

Inogen, Inc. (INGN) Accused of Misstating its Strong Sales and Financial Success

According to the complaint, on November 7, 2017, Inogen touted its strong sales and financial success, predicting "strong results in 2018…" and increased its guidance range for full year 2017 revenue. Inogen subsequently increased its FY18 guidance range, emphasizing that the company's strong direct-to-customer sales were the result of the strong sales acumen of its salesforce. These quarterly statements were often followed by significant increases in stock price that resulted in a class period high of more than $282 per share on September 14, 2018. In February 2019, a series of news articles were released criticizing the company's narrative and denouncing its sales tactics, negatively affecting the company's stock. Then, on February 26, 2019, Inogen announced poor 4Q18 and FY18 financial results, which caused Inogen's stock to fall nearly $34 per share, or more than 24% to close at $106.28 per share on February 27, 2019. The stock now trades at around $46 per share, representing another 57% decline in value.

Inogen, Inc. (INGN) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsarroyo.com
Shareholder Information Form

Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click Here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

Leo Kandinov
Robbins Arroyo LLP
5040 Shoreham Place
San Diego, CA 92122
LKandinov@robbinsarroyo.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsarroyo.com





×

StockTalk
Get our FREE StockTalk Investor Guides by sector as they are released!

Stay on top of sector specific news, get industry leaders insights and our best content, delivered to your email.

You are already a member! Please enter your password to sign in.